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Multi-drug resistant microorganisms have been a growing concern during the last
decades due to their contribution in mortality rates worldwide. Antimicrobial peptides
(AMPs) are broad spectrum antimicrobial agents that display potent microbicidal activity
against a wide range of microorganisms. AMPs generally have a rapid mode of action
that reduces the risk of resistance developing among pathogens. In this study, an
AMP derived from scorpion venom, NDBP-5.5, was evaluated against Mycobacterium
abscessus subsp. massiliense, a rapidly growing and emerging pathogen associated
with healthcare infections. The minimal bactericidal concentration of NDBP-5.5, AMP
quantity necessary to stop bacteria visible growth, against M. abscessus subsp.
massiliense was 200 µM, a concentration that did not induce hemolysis of human
red blood cells. The therapeutic index was 3.05 indicating a drug with low toxicity and
therefore good clinical potential. Treatment of infected macrophages with NDBP-5.5
or clarithromycin presented similar results, reducing the bacterial load. M. abscessus
subsp. massiliense-infected animals showed a decrease in the bacterial load of
up to 70% when treated with NDBP-5.5. These results revealed the effective
microbicidal activity of NDBP-5.5 against Mycobacterium, indicating its potential as an
antimycobacterial agent.
Keywords: AMP, antimycobacterial agents, infection, non-disulfide bridged peptide, rapid-growing mycobacteria,
scorpion venom
INTRODUCTION
Over the last decade, a significant increase in the number of studies investigating the potential
use of antimicrobial peptides (AMPs) to treat diseases has been observed (Gordon et al., 2005).
AMPs are positively charged (+1 to +9) peptides comprising 12–100 amino acids, produced by
the cells of insects, plants, amphibians, and mammals, that exert microbicidal function (Zeng
et al., 2005; Ortiz et al., 2015). Although the mechanisms involved in the microbicidal function
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of AMPs remain to be fully elucidated, studies have shown
that positively charged AMPs interact with negatively charged
microbial cell walls (Zasloff, 2002; Jenssen et al., 2006). The
mechanism underlying this interaction may be membrane
disruption and the formation of a carpet, a barrel or a membrane
clump, or internalization causing dysfunction of the intracellular
target (Powers and Hancock, 2003; Giuliani et al., 2007).
Antimicrobial peptides have been identified in the venom
of arthropods, such as wasps, scorpions, and bees. The AMPs
derived from scorpion venom can be divided into two groups
according to the presence of a disulfide bridge (DB group) or the
absence of a disulfide bridge [non-disulfide bridge (NDB) group].
Small peptides from scorpion venom belonging to the NDB
group were characterized as being fungicidal and bactericidal
(Dai et al., 2001, 2002; Zeng et al., 2004, 2013; Gao et al.,
2009). For example, ToAP2 from Tityus obscurus displayed a
low MIC and was able to destroy a Candida albicans biofilm
(Guilhelmelli et al., 2016). The mature peptide NDBP-5.5 from
Hadrurus gertschi venom (Schwartz et al., 2007) possesses 13
amino acids and also belongs to the NDB group of peptides, being
classified as NDBP-5.5, and therefore may exert microbicidal
activity.
The Mycobacterium abscessus complex is composed of rapid-
growing mycobacteria that cause human and animal infections.
Such infections predominantly affect the skin, lungs, and
connective tissue (Griffith, 2007; Cardoso et al., 2008; Kim et al.,
2008; Duarte et al., 2009). The incidence ofM. abscessus infections
has been increasing and becoming more widespread over recent
years (Lee et al., 2015). The M. abscessus complex comprises
three subspecies: M. abscessus subsp. abscessus, M. abscessus
subsp. massiliense, and M. abscessus subsp. bolletii (Adékambi
et al., 2004; Lee et al., 2015). Several cases of infection with
M. abscessus subsp. massiliense were reported in Brazil in 63
different hospitals. The bacteria recovered from theses different
outbreaks presented resistance to glutaraldehyde as well as to
antimicrobial drugs (Duarte et al., 2009). Additionally, this
subspecies of M. abscessus was shown to be more virulent and
pathogenic than the other species of the group (Sousa et al., 2010;
Shang et al., 2011). The treatment of infections caused by these
bacilli depends on the species, but involves some combination
of clarithromycin (CLR), amikacin (AMK), cefoxitin (FOX),
and/or imipenem (IPM) (Cardoso et al., 2011; Tettelin et al.,
2014). However, infections caused by drug-resistant bacilli have
emerged in recent years (Kim et al., 2008; Choi et al., 2012). Thus,
it is important to search for new drugs or molecules that could
substitute, or be combined with, existing treatments.
The aim of this study was to determine the activity, both
in vitro and in vivo, of NDBP-5.5 against M. abscessus subsp.
massiliense.
MATERIALS AND METHODS
NDBP-5.5
Peptide NDBP-5.5 (UniProt P0C8W1) was identified as
previously described (Schwartz et al., 2007) and was synthesized
by C-terminal amidation using FastBio LTDA (Ribeirão Preto,
SP, Brazil). NDBP-5.5 presented >95% of purity. The molecular
mass and sequence of the synthetic NDBP5.5 were confirmed
by MALDI-TOF/TOF MS (UltraFlex III, BrukerDaltonics,
Germany) and LIFTTM (MS/MS) as previously described
(Guilhelmelli et al., 2016).
Bioinformatic Sequence Similarity
Analysis
Multiple sequence alignment of the obtained sequences of
peptide NDBP-5.5 was performed using ClustalW2 and BioEdit
software (Larkin et al., 2007). Structural predictions, as shown in
an alpha helix diagram, were generated by the HeliQuest server1.
Peptide Stability in Aqueous Solution
Molecular dynamics (MD) simulations were performed with
Gromacs 5.1.3 (Berendsen et al., 1995; Yu, 2012) using force
field AMBER99SB-ILDN (Yildirim et al., 2010) in order to
explore the stability (or instability) of the peptide in water.
Initially, the peptide was solvated with a box cubic wall
distance of 10 Å using water model TIP3P (Mahoney and
Jorgensen, 2000). The system was neutralized by adding the
required number of counter ions. The particle mesh Ewald
method (Darden et al., 1993) was used to evaluate electrostatic
interactions with periodic boundary conditions considered in
all directions from box. The system was initially subjected to
minimization using the steepest descent energy. The simulations
were completed when the tolerance of 1000 kJ/mol was no
longer exceeded. The next four stages consisted of a series of
equilibration simulations to slowly relax the system without
deviating from the initial conformation. The first two stages
consisted of 50 ps MD simulations in NVT and NPT ensembled
at 300 K with a restraint of 50 kcal/mol/Å on the peptide
atoms. In the next stage, the simulations were performed
during 0.5 ns without restraint in NPT ensembled at 300 K.
Finally, the simulations were performed for 100 ns with a
constant temperature of 300 K, 1 atm pressure, time-setup of
2 fs, and without any restriction of peptide conformations.
All information concerning the trajectory of these times were
collected every 50 ps. The equilibration of the trajectory was
evaluated by monitoring the equilibration of quantities, such as
the root-mean-square deviation (RMSD) (Coutsias et al., 2004)
of the non-hydrogen atoms, kinetic energy, total energy, and
potential energy.
The program g_cluster (GROMACS tool) was used to
determine the conformations that best represented the peptide
structures of the entire trajectory. The algorithm gromos, as
described by Daura et al. (1999), was selected for this purpose.
A cutoff = 0.2 nm for the clusters was used considering the
profile of the RMSD. The clusters were determined using the
non-hydrogen atom RMSD values.
Mycobacterium abscessus subsp.
massiliense Cultures
The mycobactericidal activity of NDBP-5.5 was determined
in vitro using three clinical isolates randomly selected from
1http://heliquest.ipmc.cnrs.fr
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FIGURE 1 | Spectrophotometry and bioinformatic analysis of the NDBP-5.5. (A) Mass spectrometry of the synthesized NDBP-5.5 peptide obtained by MALDI
TOF/TOF. (B) Mass fragmentation pattern (MS/MS) obtained from the monoisotopic mass [M+Na]+ = 1532.73 Da ion. (C) Helicoidal wheel diagram (yellow
residues: non-polar and hydrophobic; purple residues: polar; gray residues: neutral; pink residue: asparagine). C, carboxyl terminal end; N, amino terminal end.
(D) Multiple alignment of the sequences of NDBP-5.5, IsCT, Meucin-13, Meucin-18, VmCT-1, StCT-1, Hp1090, and Pantinin-1. Blue, identical amino acids; green,
highly homologous amino acids to those in the NDPB-5.5 sequence; yellow, higher homology between the peptides. (E) RMSD dynamic profiles obtained for the
MD1 (purple) and MD2 (green) simulations of NDBP-5.5 peptide over 100 ns. (F) Cluster analysis of the trajectory obtained for a cutoff of 0.2 nm in order to select
the main structures during the simulations. The clusters were determined using the non-hydrogen-atom RMSD values. Inserted figures shown at the top left
represent 10 cluster structures from MD1 (left) and MD2 (right) independent simulations.
our laboratory collection: M. abscessus subsp. massiliense
GO01, GO06, and GO08 (Cardoso et al., 2008) and the
reference strain CRM0020 (Duarte et al., 2009). The
bacteria were grown in Mueller–Hinton medium (MH,
HIMEDIA) for 3 days at 35◦C. Then, the cultures were
adjusted to 1.5 × 108 CFU/mL (0.5 McFarland scale)
to determine the minimal bactericidal concentration
(MBC).
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Mycobacterium abscessus subsp. massiliense GO06 was used
for the in vivo experiments (mice intravenous infection) (Sousa
et al., 2010; das Neves et al., 2016). The bacterial suspension was
diluted in PBS 0.05% Tween 80 and adjusted to 1× 106 CFU/mL.
Animals
Macrophages were obtained from the bone marrow of BALB/c
mice. IFN-γ KO mice were used to test the effect of
peptide NDBP-5.5 on the treatment of M. abscessus subsp.
massiliense infection. Female mice, of 7–9 weeks-of-age, were
obtained from the animal facilities at the Institute of Tropical
Pathology and Public Health at the Federal University of
Goiás (IPTSP/UFG). All animal handling procedures and
protocols were performed according to the National Counsel for
animal experimentation recommendations (Conselho Nacional
de Controle de Experimentação Animal -CONCEA). The Animal
Ethics Committee at the Federal University of Goias approved the
protocols (Comitê de Ética no uso de animais da Universidade
Federal de Goiás (No: 016/14).
Minimal Bactericidal Concentration
(MBC) of NDBP-5.5
The MBC determination was adapted from ATS/IDSA guidelines
(Griffith et al., 2007). The lyophilized peptide NDBP-5.5 was
diluted in 3% DMSO. M. abscessus subsp. massiliense cultures,
grown as described previously, were adjusted to 100 CFU/100 µL
and added to 96-well plates. The peptide solution was serially
diluted in PBS (13–400 µM), and 100 µL of each dilution
was added to the wells. Each NDBP-5.5 peptide dilution was
tested in triplicate. The plates were incubated for 3 days at
35◦C. All test plates contained control wells of medium only,
M. abscessus subsp. massiliense isolates as positive controls,
or M. abscessus subsp. massiliense isolates treated with CLR
(1.34 µM) as a negative control. After 3 days of culture, the
wells were homogenized and transferred to an MH agar plate
to calculate the number of CFU per treatment. The MBC
was determined and the percentage of inhibition in relation
to bacterial growth in the medium without treatment was
calculated.
FIGURE 2 | Minimal bactericidal concentration (MBC) of NDBP-5.5 against Mycobacterium abscessus subsp. massiliense. Three different M. abscessus
subsp. massiliense clinical isolates and the reference strain CRM0020 were cultivated with different concentrations of NDBP-5.5 for 24 h. The percentage of growth
inhibition was calculated by plating serial dilutions of each culture and determining the number of colony-forming units (CFUs). (A) Isolate GO01; (B) isolate GO06;
(C) isolate GO08; (D) reference strain CRM0020. The MBC was determined as the lowest concentration that completely inhibited mycobacterial growth. These
results are the mean values of three independent experiments.
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Hemolysis Assay
The toxicity of NDBP-5.5 against human red blood cells was
evaluated as described previously (Ramírez-Carreto et al., 2012).
Ten milliliters of peripheral blood from a healthy subject (without
any symptoms of disease) were collected. The protocol was
approved by the Ethics Committee of the Federal University of
Goias (protocol number: 055/2009) and the participant signed
a consent form. Briefly, red blood cells were obtained by
centrifugation of the blood at 1000 × g. The cells were then
washed with PBS, adjusted to 1× 108 cells/mL, and 100 µL were
added to the wells of a 96-well plate. The NDBP-5.5 solution
was diluted to 8, 4, 2, and 1× the peptide MBC value (200 µM)
and 100 µL was added to the wells. The plates were incubated
for 1 h at 37◦C, and after this period they were centrifuged
(1000 × g) and the absorbance was determined at 540 nm. Red
blood cells treated with Triton-100X (0.1%) were used as positive
controls and red blood cells only were used as negative controls.
The assay was performed in triplicate and repeated twice. The
percentage of hemolysis was obtained using the formula: % of red
cell lysis= 100× [(test-PBS)/(Triton-PBS)].
The therapeutic index (TI) was determined according to Wang
et al. (2009) by dividing the concentration of NDBP-5.5 that
caused 10% hemolysis by the MBC value.
Mycobactericidal Activity of NDBP-5.5 in
Bone Marrow-Derived Macrophages
Infected with M. abscessus subsp.
massiliense
BALB/c mice (n = 4) were euthanized and the femur bone
marrow was extracted, homogenized and plated with 10 ng/mL
of GM-CSF as described previously (Becker et al., 2012). After
3 days of culture, the medium was supplemented with 10 ng/mL
of GM-CSF. After 7–10 days of culture, the macrophages
were transferred to a 96-well plate at 105 cells/well. After a
1 h incubation at 37◦C in a CO2 incubator, 106 CFU/well
of M. abscessus subsp. massiliense were added to the cultures
[multiplicity of infection (MOI), 10:1] and further incubated
for 3 h. Then, the cell cultures were washed with RPMI-1640
(HIMEDIA), containing 10% fetal bovine serum, 1 mM sodium
pyruvate, 100 U/mL penicillin, 100 g/mL streptomycin, 2 mM
L-glutamine, and 2 mM non-essential amino acids.
After this procedure, the infected macrophages were treated
with 200 µM of NDBP-5.5 (MBC= 200 µM) prepared in RPMI-
1640 media. After 72 h, the cells were treated with 200 µL
of deionized water, and after homogenization, the suspensions
were plated on MH agar plates for culturing to determine the
number of CFU. Controls containing only infected macrophages
or macrophages treated with CLR were added to all of the 96-well
test plates.
In vivo Mycobactericidal Activity of
NDBP-5.5
IFN-γ KO mice were intravenously infected with 106 CFU of
M. abscessus subsp. massiliense. After 18 days of infection, the
mice were treated with NDBP-5.5 (2 mg/kg, n = 12 animals; or
1 mg/kg, n = 12 animals) or CLR (200 mg/kg, n = 12 animals)
over 8 consecutive days. An infection group treated with PBS
(n = 12) was used as a control. The animals were treated by
intraperitoneal injection with a volume of 100 µL as previously
described (das Neves et al., 2016).
To monitor the infection with M. abscessus subsp. massiliense,
the day following infection and 18 days post-infection, three
animals per time and group were euthanized, and the lungs,
spleens, and livers were collected to determine the bacillary
count.
Twenty-seven-days post infection (1 day after the end of
treatment), the animals were euthanized (n = 6), and spleens,
livers, and lungs were collected to determine the bacillary load.
To establish the bacterial load, the organs were homogenized
in PBS 0.05% Tween 80, serially diluted, and plated in MH agar.
The percentage reduction in bacterial numbers was calculated
using the number of CFU obtained from the organs of animals
infected with M. abscessus subsp. massiliense without treatment
and the number of CFU from the groups treated with NDBP-5.5
or CLR.
Histology
After 28 days of infection, mice were euthanized and the organs
were collected. The right lung caudal lobe from each animal
was fixed in 10% paraformaldehyde and blocked in paraffin. The
tissues were sectioned (at 5-µm), stained with hematoxylin and
eosin, and observed under an optical microscope (Axio scope A1;
Carl Zeiss, Oberkochen, Germany).
Statistical Analysis
The data were tabulated using Excel software and the average and
standard deviation values were calculated. To evaluate statistical
differences among groups, the software GraphPad Prism 6.0 was
used. The variances among groups were evaluated by one-way
ANOVA, followed by the Tukey test. Differences were considered
statistically significant when p< 0.05.
FIGURE 3 | Hemolytic activity of NDBP-5.5. Human red blood cells were
incubated with the NDBP-5.5 in concentrations ranging from 6.25 to
1600 µM. The therapeutic index (TI) calculated based on the percentage of
hemolytic activity at the MBC is shown.
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RESULTS
Peptide Characteristics
A previously described cDNA sequence of a peptide derived
from H. gerstchi venom (Schwartz et al., 2007) and comprising
13 amino acids (IFSAIAGLLSNLL) with C-terminal amidation,
namely NDBP-5.5, was synthetized and the sequence was
confirmed by MALDI-TOF/TOF (Figures 1A,B). The predicted
secondary structure1 revealed an alpha helix with amphipathic
characteristics containing a hydrophilic region (A,S,S,G,N,A)
and a hydrophobic region (L,F,L,I,L,I,L) (Figure 1C). Sequence
alignment of NDBP-5.5 with other scorpion venom peptides
from the same family of peptides (from the NDB group) showed
highest similarity (69.2%) with Meucin-13 from Mesobuthus
eupeus venom (Figure 1D). MD simulations from the PEP-FOLD
model were performed in order to verify the stability of the
NDBP-5.5 in water under two independent trajectories (different
initial conditions). Figures 1E,F shows the RMSD evolution
from initial model (PEP-FOLD structure) for MD1 and MD2
simulations. For both simulations, the peptide was not able to
FIGURE 4 | Effect of NDBP-5.5 treatment of macrophages infected with different strains of M. abscessus subsp. massiliense. Bacillary load after
treatment of macrophages infected with (A) isolate GO01, (B) isolate GO06, (C) isolate GO08, (D) CRM0020, and respective controls. (E) Shows the percentage of
bacillary load reduction among all strains treated with NDBP-5.5 or CLR. These results are the mean values of three independent experiments. ∗p < 0.05 statistically
significant difference between the test groups and the infected only group.
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remain stable around a particular conformation, even to any
conformation other than the helical structure. It can be verified
from cluster analysis of the trajectory, that most of the structures
were unstable for any time during the simulation (Figure 1F).
NDBP-5.5 Antimicrobial Activity and
Hemolysis Induction
NDBP-5.5 inhibited the growth of all M. abscessus subsp.
massiliense isolates evaluated (Figure 2). Using a range of clinical
isolates and a reference strain (CRM0020), the MBC of NDBP-5.5
was determined to be 200 µM.
As shown in Figure 3, NDBP-5.5 displayed low hemolytic
activity. When the peptide was used at a concentration eight-
times higher (1600 µM) than that of the MIC, 39% hemolysis
occurred (Figure 3). The concentration of NDBP-5.5 that caused
10% hemolysis was calculated (611.8 µM) and, as suggested by
Wang et al. (2009), used to estimate the TI, by dividing by the
MBC value (200 µM). The TI was determined as 3.05.
Antimicrobial Activity of NDBP-5.5
against M. abscessus subsp. massiliense
in Infected Macrophages
Since NDBP-5.5 presented low toxicity, we decided to test its
function against phagocytosed bacteria. The treatment of infected
macrophages (MOI, 1:10) with NDBP-5.5 or CLR reduced the
bacterial load at similar levels (Figure 4). The highest bacterial
load reduction was observed with the reference strain (60%
reduction; Figure 4E).
NDBP-5.5 Treatment of IFN-γ KO Mice
Infected with M. abscessus subsp.
massiliense
Mice susceptible to M. abscessus subsp. massiliense infection were
used to test the in vivo activity of NDBP-5.5. Using 2 mg/kg
of NDBP-5.5, the bacterial load was significantly reduced in
the lungs and liver. The bacterial load reduction observed at
this dosage (2 mg/kg) was similar to that observed for CLR
(Figures 5A–C). Evaluating the lung inflammatory lesions of the
infected animals, it was possible to observe diffuse inflammatory
lesions at 28-days-post-infection (Figure 6A), that were reduced
when the animals were treated with CLR (Figure 6B). Treatment
with NDBP-5.5 at 1 mg/kg resulted in inflammatory lesions that
were similar to the lesions observed in the lungs of infected
animals that were not treated with NDBP-5.5 (Figure 6C).
The lung lesions induced by infection in IFN-γ KO mice were
drastically reduced when the animals were treated with NDBP-5.5
at 2 mg/kg (Figure 6D). The score of the lesions were evaluated
and showed that mice treated with NDBP-5.5 (2 mg/Kg) had
reduced inflammatory lesions when compared to infected and
not treated animals (Figure 6E).
FIGURE 5 | Bacillary load reduction in IFN-γ KO mice infected with M. abscessus subsp. massiliense. (A) Lung bacillary load; (B) spleen bacillary load; (C)
liver bacillary load. (D) Percentage of bacillary load reduction in the three different organs. These results are the mean values of three independent experiments.
∗p < 0.05 statistically significant difference between the test groups and the only infected group and the PBS treatment group. #p < 0.05 statistically significant
difference between the CLR and NDBP-5.5 treated groups.
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FIGURE 6 | Lung inflammation in mice infected with M. abscessus
subsp. massiliense and treated with NDBP-5.5 (1 or 2 mg/kg) or CLR.
After 8 days of treatment, the animals were euthanized and their lungs were
processed and stained with hematoxylin and eosin. (A) Infected control group:
diffuse lung infiltration of mononuclear cells and increase of arteriolar wall
thickness. (B) Group infected and treated with CLR: periarteriolar
mononuclear cells cuffs; alveolar septum thickness. (C) Group infected and
treated with NDBP-5.5 (1 mg/kg): diffuse lung infiltration of mononuclear cells
and increase of arteriolar wall thickness. (D) Group infected and treated with
NDBP-5.5 (2 mg/kg): discrete mononuclear cells infiltration. (E) Histology
score of lesion areas. Score obtained by AxioVision 4.9.1 software, through
the ratio between lesioned area and the whole image. The data were
evaluated in the whole lung. Values showed in percentage (%). ∗p < 0.05
statistically significant difference between the test groups and the group only
infected.
DISCUSSION
Our findings demonstrate, for the first time, the antimicrobial
activity of a peptide from scorpion venom against rapid-growing
mycobacteria. NDBP-5.5 is an amphipathic peptide from the
family of NDB peptides derived from the venom of H. gertschi
that showed activity against M. abscessus subsp. massiliense,
a rapid-growing Mycobacterium that has been associated with
healthcare infections. NDBP-5.5 showed a MBC of 200 µM
and, at the concentration tested, was not hemolytic. NDBP-5.5
reduced the bacterial load of infected macrophages, as well as
infected mice, to similar levels as CLR, one of the antibiotics used
to treat infections with these bacteria.
In silico sequence analysis of NDBP-5.5 revealed polar
and hydrophobic regions suggesting amphipathic properties
(Wimley, 2010). The high similarity observed between NDBP-
5.5 and Meucin-13 peptide from M. eupeus venom, which has
potent activity against Gram-positive bacteria (Gao et al., 2009),
suggested that NDBP-5.5 may also exert bactericidal properties
as both peptides share the same conserved hydrophobic amino
acids.
NDBP-5.5 presented an MBC of 200 µM (266 µg/mL)
against M. abscessus subsp. massiliense. This MBC value was
high compared with that of other similar peptides, such as
Polydim-1 derived from wasp (Polybia dimorpha) venom that
presented an MBC of 60.8 µg/mL (12.5 µM) against the same
species of mycobacteria (das Neves et al., 2016). The MBC
was also high compared with other scorpion venom-derived
peptides tested against other microorganisms (1–200 µM) (Dai
et al., 2001; Gao et al., 2009; Yan et al., 2011; Ramírez-Carreto
et al., 2012, 2015; Zeng et al., 2013); however, these peptides
were not evaluated for their activity against mycobacteria. The
ToAP2 from T. obscurus, which belongs to the same NDB
family of peptides, presented a varied MBC of 3.12 to 200 µM
when tested against Candida spp. (Guilhelmelli et al., 2016).
Despite the high concentration needed for mycobactericidal
action, NDBP-5.5 showed low toxicity even at concentrations
eight-times higher than the MBC, corresponding to a TI of 3.05.
By contrast, peptide Meucin-13 presented high toxicity at its
MIC concentration (MIC = 6.5 µM) against bacteria and fungi
(Gao et al., 2009). TIs varying from 0.5 to 12.1 have been found
for AMPs tested against Mycobacterium tuberculosis (Ramírez-
Carreto et al., 2015), nonetheless none of those peptides were
tested in animals to confirm their ability to treat infection.
Thus, NDBP-5.5 could be a promising drug candidate because
it exerts mycobactericidal activity accompanied by low toxicity
in vivo.
Meucin-13, which shows high similarity to NDBP-5.5, induces
membrane modifications that culminate in the lysis of Bacillus
megaterium cells (Gao et al., 2009). MD analysis revealed the
instability of NDBP-5.5 in aqueous solution, suggesting its
necessity of a non-polar environment such as membrane for its
stabilization, and hence its possible target of action. Although not
shown, MEV analysis ofM. abscessus subsp.massiliense treatment
with NDBP-5.5 induced agglomeration of the bacilli but did not
appear to alter the mycobacterial envelope structure. It is possible
that NDBP-5.5 acts by modifying the cell wall, without forming
pores or lesion, but instead by parallel lining of the cell wall
(carpet) causing perturbation of the osmotic mechanisms and
consequently allowing leakage of intracellular content (Powers
and Hancock, 2003; Nguyen et al., 2011), but this hypothesis
needs further testing.
There is a direct relationship between polar charges in
the hydrophilic region of a peptide and its hemolytic action
(Chen et al., 2007). The presence of two polar residues in
the hydrophilic region of NDBP-5.5 may be responsible for
the low rate of cytotoxicity observed, due to reduced contact
with the erythrocyte membrane. Accordingly, the Pantinin-3
AMP presented three polar residues, and was more toxic to
erythrocytes than Pantinin-2 AMP that possessed only two
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polar residues in the same hydrophilic region (Zeng et al.,
2013). Similarly, VmCT2 displayed three polar residues in its
hydrophilic region and was shown to be more hemolytic in higher
concentrations than VmCT1 with only one polar residue in the
same region (Ramírez-Carreto et al., 2012).
Our experiments in infected macrophages revealed that the
activity of NDBP-5.5 was not only in vitro, as a reduction
of approximately 50% of the bacterial load was observed in
infected macrophages, similar to the effects seen with CLR.
This microbicidal action indicated the potential application of
NDBP-5.5 in the treatment of infected animals. IFN-γ KO
mice that are more susceptible to mycobacterial infections
were used to test this hypothesis (Rottman et al., 2007; Shang
et al., 2011). NDBP-5.5 treatment significantly reduced the
bacillary load in the lungs and liver of M. abscessus subsp.
massiliense-infected IFN-γ KO mice in a similar manner as other
AMPs against Mycobacterium tuberculosis (Rivas-Santiago et al.,
2013).
In this study, it was not possible to determine the mechanism
of microbicidal induction by NDBP-5.5. The specific activity of
this AMP on mycobacteria and on macrophages may be mediated
via different targets and different modes of action.
The administration of a combination of antimicrobials can
reduce the propensity for developing resistance and is a
promising strategy to treat diseases caused by drug-resistant
bacteria (Huang et al., 2010). NDBP-5.5 could therefore be
combined with conventional antimicrobials to treat rapid-
growing mycobacterial infections. The treatment of this group
of mycobacteria requires more than one drug to effectively clear
the pathogen. To test whether NDBP-5.5 would have an addictive
or synergic effect with CLR, M. abscessus subsp. massiliense
was exposed to different drug concentration combinations. In
vitro, no association between the tested drugs was observed
(data not shown). Thus, it seems that the major advantage
supported by the data presented here is that the peptide might
reduce the extensive inflammatory reactions induced by the
infection nonetheless, bacterial clearance will need the aid of
others antibiotics.
In summary, the AMP NDBP-5.5 derived from the H. gertschi
scorpion displayed antibacterial activity against M. abscessus
subsp. massiliense, both in vitro and in vivo, along with low
hemolytic activity. Further studies are now needed to understand
the mechanism of action of this peptide before it can potentially
be used as an auxiliary treatment for rapid-growing mycobacteria
infections.
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